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This double-blind, randomized, placebo crossover study
was used to evaluate the effects of a cholinesterase in-
hibitor-slow-release pyridostigmine(180mg orally every
12 hours)-on the anticholinergic and antiarrhythmic
properties of disopyramide. Quantitative side effects
questionnaire scores were used to guide disopyramide
administration in 20 men with ventricular tachycardia.
Disopyramide was given to each patient both with pla-
cebo and with active pyridostigmine. The maximal ad-
ministered dose for each regimen was used in conjunc-
tion with corresponding questionnaire scores to calculate
an index or estimate of the maximal tolerable dose of
disopyramide. Additional evaluations performed at
baseline and at each maximal administered dose regimen
included tear and saliva quantitation, 24 hour electro-
cardiogram (ECG), exercise testing and programmed
ventricular stimulation.
Results showed that the maximal administered dose
of disopyramide was greater with active pyridostigmine
than with placebo: 295 ± 75 versus 245 ± 100mg every
6 hours (p < 0.05). The calculated maximal tolerable
dose was substantially greater in the presence of pyri-
Disopyramide is clinically effective in the management of
ventricular and supraventricular arrhythmias (including atrial
fibrillation and those due to the Wolff-Parkinson-White syn-
drome) (1-5) . The potential clinical usefulness of disopyr-
amide has not been fully realized because of two significant
adverse effects: aggravation of congestive heart failure in
susceptible patients and precipitation of anticholinergic
symptoms (2-4,6). Although the former occurs infre-
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dostigmine: 355 ± 90 versus 260 ± 115 mg every 6
hours (p < 0.001). Maximal side effects questionnaire
scores also reflected decreased anticholinergic activity in
the presence of pyridostigmine compared with placebo:
101.9 ± 2.2 versus 104.6 ± 2.8, respectively (p < 0.005).
Baseline tear and saliva production was significantly re-
duced during disopyramide therapy, but was restored
toward normal by the addition of pyridostigmine.
Analysis of 24 hour ECGs, exercise tests and pro-
grammed stimulation showed that pyridostigmine had
no effect on the following properties of disopyramide:
1) reduction of ventricular tachycardia, couplets and
premature ventricular complexes;2) induced ventricular
tachycardia cycle length; 3) refractory periods; and 4)
QT intervals. At similar doses of disopyramide, peak
and trough blood levels were unaffected by pyridostig-
mine.
It is concluded that pyridostigmine selectively re-
verses the troublesome anticholinergic side effects of di-
sopyramide without affecting its electrophysiologlc or
antiarrhythmic properties.
(J Am Coli Cardiol 1987;10:633-41)
quently , it is potentially life-threatening and an alternative
therapy should be sought for patients at risk of this com-
plication (6). In contrast. troublesome anticholinergic symp-
toms, including urinary hesitation and retention, dry mouth
or eyes and constipation occur in 20 to 67% of patients
receiving disopyramide (2-4), and these represent the major
impediments to increased clinical use of disopyramide . Fur-
thermore, a desire to avoid these anticholinergic symptoms
has led physicians (and patients) to seek alternative thera-
peutic agents in cases where disopyramide might be clini-
cally effective (4,7 ).
We recently reported the results of a pilot study (8) in-
dicating that sustained-release pyridostigrnine, a cholines-
terase inhibitor used in the treatment of myasthenia gravis,
may be effective in preventing the anticholinergic side ef-
fects attributable to disopyramide or relieving them once
they have occurred , or both. The nature , extent and clinical
0735-1097/87/$3 .50
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Figure 1. Study design of the protocol followed for
a patient achieving maximal tolerable doses (MTD)
of 400 an? 100 mg of disopyramide (DISOP) during
study penods I and II, respectively. Vertical hash
marks show the disopyramide dose administered.
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applicability of this disopyrarnide-pyridostigmine interac-
tion are the subject of this prospective study.
Methods
Study design (Fig. 1). This was a double-blind, ran-
domized, placebo crossover study in 20 men, comparing
disopyramide (and placebo) with the combined regimen of
disopyramide plus sustained-release pyridostigmine. After
the completion of baseline evaluations of anticholinergic
and electrophysiologic variables (discussed later), patients
received increasing doses of disopyramide during a titration
period until a maximal administered dose was determined
for each treatment regimen. This dose was defined as the
highest disopyramide dose causing trivial (tolerable) or no
anticholinergic symptoms as indicated by a side effects ques-
tionnaire score. The maximal administered dose was further
limited to 300 to 400 mg every 6 hours, predetermined for
each patient on the basis of weight and clinical history. This
dose was then continued for 24 to 48 hours of therapy during
a steady state period. Quantitative determinations of anti-
arrhythmic and anticholinergic end points made during base-
line study were repeated during the steady state of each
treatment regimen. After completion of the initial arm of
the study, both study drugs were discontinued for 24 to 36
hours to allow adequate washout before the crossover arm
of the study.
Patient selection: inclusion criteria. Because one of
the study end points was the development of anticholinergic
symptoms secondary to disopyramide, and women are re-
ported to have a lower incidence of these side effects (4),
only men were included. Subjects of any age were eligible
if they were undergoing serial pharmacologic-electrophys-
iologic testing (9,10) for control of clinically diagnosed
sustained ventricular tachycardia or fibrillation together with
arrhythmias documented in the unmedicated state in one or
more of the following ways: I) Holter monitoring: ~30
ventricular premature complexes/h (Lown grade 2 [II]),
complex ventricular premature complexes (muItiforms ==
Lown grade 3 or couplets = Lown grade 4a [11]) or ~3
successive ventricular premature complexes (Lown grade
4b [II]); 2) programmed electrical stimulation: induced ven-
tricular tachycardia (seven or more beats) or ventricular
fibrillation; and 3) exercise stress testing: exercise-induced
ventricular tachycardia (seven or more beats).
Exclusion criteria. Patients were excluded if they had
current evidence of congestive heart failure, a history of
initiation or exacerbation of congestive heart failure or ven-
tricular arrhythmias with disopyramide or known hypersen-
sitivity to disopyramide or pyridostigmine. Patients unable
to undergo 48 hours of baseline evaluation in the absence
of antiarrhythmic agents were also ineligible.
Twenty-three patients were asked to participate in this
trial. Three patients declined (two did not want to participate
in any "experimental" protocol and one did not want to
add any extra days to his hospital stay). Therefore, 20 pa-
tients were studied. This protocol was approved by the Mon-
tefiore Institutional Review Board on February 11, 1983.
All patients signed an informed written consent, approved
by the Review Board, before receiving therapy as part of
this protocol.
Medication administration. Patients received 100 to
400 mg of disopyramide (Norpace, Searle Laboratories)
orally every 6 hours during the titration periods. The patients
began with lower doses and received two or more doses at
every dose level (Fig. I). They completed a side effects
questionnaire before each disopyramide dose, indicating the
nature and severity of anticholinergic side effects, if present.
If no significant side effects were reported and physical
examination revealed no change in hemodynamic status, the
disopyramide dosage was then increased by 100 mg and the
process repeated until the maximal administered dose was
reached as previously defined. The titration schedule used
in the crossover arm of the protocol was always identical
to that used in the initial arm. This rapid titration of diso-
pyramide dosages is consistent with usual procedures during
serial pharmacologic-electrophysiologic testing at our in-
stitution (9,10).
Sustained release pyridostigmine (Mestinon Timespan,
Roche Laboratories) or blinded placebo was administered
in a dosage of 180 mg every 12 hours. The sustained release
form was chosen to reduce the incidence of sudden extreme
cholinergic side effects sometimes encountered with the im-
mediate release form (8).
Study Data: Anticholinergic Evaluation
Side effects questionnaire. This questionnaire consisted
of 20 questions inquiring about the most commonly re-
ported side effects of disopyramide (Table 1) (12). Patients
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were asked to rate themselves on a scale from I to 9, in-
dicating the severity of the side effects present. A "normal"
value for each question was defined during the baseline
period as having a value of 5; consequently. a normal total
score was 20 x 5 = 100. Anticholinergic side effects
corresponded to numeric values > 5. and total scores > 100
refl ected proportional increases in the severity of the anti-
cholinergic symptoms reported, A total score of 100 to 101
corresponded to no anticholinergic symptoms, a score of
102to 103 to minimal symptoms, 104to 105to mild symp-
toms. 106to 107to moderate symptoms and 2: 108 to severe
symptoms.
Patients completed the questionnaire with assistance at
least three times during the baseline period to ensure clarity
and familiarity, The questionnaire was then completed with-
out assistance before each dose of disopyramide received
during the study.
Careful attention was directed toward the patients' ability
to urinate. Patients were instructed to void before question-
naire completion, and the response to the question on uri-
nation was noted both together with and separately from the
total score.
Calculation of maximal tolerable dose. For statistical
comparison of maximal administered doses, the severity of
anticholinergic side effects was incorporated into an index
as follows. In patients reporting no anticholinergic symp-
toms (a maximal questionnaire score of 100 to 101 ), the
maximal tolerable dose was considered to be 100mg greater
than the maximal administered dose. In patients reporting
minimal or mild symptoms (score 102 to 105), the maximal
tolerable dose was the maximal administered dose. In pa-
tients reporting moderateor severe symptoms (score 2: 106),
the maximal tolerable dose was 100 mg less than the dose
of disopyramide producing these side effects.
Schirmer tear production test. This test is used by
ophthalmologists to quantitate tear production (13). After
the instillation of a drop of topical ophthalmic anesthetic
(Alcaine, Alcon Laboratories), a piece of standard filter
paper was hung over the corner of the lower lid. The paper
acted as a wick, absorbing lacrimal fluid for a period of 3
minutes, after which time the number of millimeters of
moistened paper was measured. This test was repeated four
Table I. Side Effects of Disopyramide
Dry mouth/tongue/nose/eyes/throat
Urinary difficulties/retention/frequency
Constipation
Abdominal discomfort
Blurred vision
Fatigue/muscle weakness
Nausea
Headache
Dizziness
Shortness of breath
Aches and pains
Chest pain
Diarrhea
Vomiting
Syncope
Anorexia
Nervousness
Palpitations
Depression
times (twice in each eye) during the baseline period and
again during the steady state periods of each arm of the
study.
Saliva production test. The amount of saliva production
in response to a standard stimulus in a measured amount of
time was recorded (14). Patients were instructed to brush
their teeth with a toothbrush and water only. They were
then given a lemon-flavored lozenge and told to collect all
saliva produced in a clean cup. The first 3 minutes of saliva
collection were discarded to allow achievement of maximal
secretory rates (14). Two successive 3 minute collections
were then made, and the volumes recorded. This procedure
was repeated twice (a total of four measurements) during
baseline and during each steady state arm of the study.
Arrhythmia and Electrophysiologic Evaluation
Ambulatory electrocardiographic (ECG) monitoring.
This was carried out for 24 to 48 hours in each patient at
baseline (in the absence of antiarrhythmic agents) and during
the steady state periods of treatment with disopyramide alone
(that is. plus pyridostigmine placebo) and disopyramide plus
active pyridostigrnine. Recorded data included the mean
number of ventricular premature complexes per hour and
the maximal grade of ventricular arrhythmia (Lown clas-
sifi cation [I 11).
Programmed electrical stimulation of the ventricles.
This was carried out using a transvenous catheter electrode
and up to three extrastimuli in a similar manner during
baseline, disopyramide and disopyramide plus pyridostig-
mine therapy according to the standard protocol at our in-
stitution (9,10). Baseline stimulation was carried out a min-
imum of five half-lives after the discontinuation of other
antiarrhythmic agents. Repeat stimulation was carried out
after no fewer than four doses at the maximal administered
dose during steady state periods. Recorded data included
effective refractory periods (10) during pacing at standard-
ized rates, the QTc interval. the method of induction of
ventricular tachyarrhythmia, the tachycardia cycle length
and the method of tachycardia termination.
Stress testing. This was carried out using a bicycle er-
gometer to evaluate the role of exercise in the patient's
clinical arrhythmia and his exercise tolerance on the various
study regimens. Exercise testing is part of the standard phar-
macologic-electrophysiologic assessment protocol at our in-
stitution. Exercise during continuous ECG monitoring was
carried out using a similar protocol at baseline and during
disopyramide and disopyramide plus pyridostigmine ther-
apy. Recorded data included the nature and frequency of
arrhythmia during baseline, exercise and recovery periods,
the number of minutes exercised and the maximal heart rate,
blood pressure and work load achieved.
Assessment of pharmacokinetics. Peak and trough blood
levels of disopyramide (sampled 2 and 5 hours after admin-
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istration, respectively) were drawn once at every disopyr-
amide dose level during both arms of the protocol. The
disopyramide dosing schedule used was always identical
during both arms of the protocol, and blood levels drawn
after analogous doses were compared.
Statistical methods. The crossover nature of this study
allowed the use of the paired t test (15). Fisher's exact test
was used for analysis of dichotomous variables. The chi-
square test was used for proportional comparisons. Data
were considered significant at the 5% level (that is, p :::;
0.05). Randomization to receive active or placebo pyrido-
stigmine first was accomplished using a boxed list of random
numbers. Values are expressed as mean values ± SD.
Results
Demographic data. Twenty men with ventricular tachy-
cardia were enrolled in this study (Table 2). The mean age
was 60 ± II years (range 33 to 74). Sixteen patients had
coronary artery disease with a history of previous myo-
cardial infarction. Two had cardiomyopathy, and one patient
each had arrhythmogenic right ventricular dysplasia and an
idiopathic left ventricular aneurysm. The group had a mean
left ventricular ejection fraction of 0.38 ± 0.12 (range 0.21
to 0.61) determined by cardiac catheterization or radio-
nuclide studies. Three patients were classified in New York
Heart Association functional class I; the majority (13 pa-
tients) were in class II, and 4 patients were in class Ill. All
Table 2. Patient Characteristics
patients had documented evidence of ventricular tachycardia
before entry into the study. The group had undergone, with-
out success, a mean of 3.1 ± 1.1 antiarrhythmic agent trials
(range I to 5) with both standard and experimental agents
before this study. Three patients had received a trial of
disopyramide therapy before entering this study. One patient
was receiving bethanechol (Urecholine, Merck, Sharp &
Dohme) throughout the study for symptomatic benign pros-
tatic hypertrophy.
Ten patients received disopyramide alone (placebo) dur-
ing the initial arm of the protocol, followed by disopyramide
plus pyridostigmine during the crossover arm. The remain-
ing 10 patients received the two treatment regimens in the
reverse order.
Seventeen patients successfully completed the protocol.
The patient receiving bethanechol for prostatic hypertrophy
developed urinary retention during the crossover arm of the
study while receiving disopyramide alone. He had experi-
enced no urinary symptoms during therapy with disopyr-
amide plus pyridostigmine. One patient developed an idio-
syncratic hypersensitivity reaction to disopyramide, with
fever, rash, eosinophilia and evidence of glomerulonephri-
tis. Repeat administration confirmed that disopyramide was
the offending agent. One patient developed hypotension
during the crossover arm of the study while receiving di-
sopyramide alone. This patient had an ejection fraction of
0.52; he had undergone coronary bypass surgery 32 days
before this event. The cause of his transient hypotension
Baseline NYHA No. of
Age Heart Ejection Functional Previous
Patient No. (yr) Disease Fraction Class Drug Failures
I 61 CAD,CABO 0.31 1II 3
2 69 CAD,HTN 0.34 II 4
3 33 ARVD 0.58 II 2
4 73 CAD 0.22 II 5
5 69 CAD,CABO 0.52 1II 2
6 62 CAD,CABO 0.24 II 5
7 63 CAD,CABO II 2
8 41 CAD 0.32 I 2
9 65 DCM II 3
10 66 CAD,HTN 0.36 III 3
II 61 CAD 0.30 II 3
12 58 CAD 0.46 II 3
13 46 DCM 0.45 I 2
14 66 CAD 0.21 II 3
15 61 CAD 0.28 II 3
16 57 CAD, CABO 0.36 II 2
17 49 ANE 0.61 II 4
18 74 CAD 0.39 II 5
19 69 CAD 0.38 I 4
20 57 CAD,CABO,DCM 0.42 III I
ANE = idiopathic left ventricular aneurysm; ARVD = arrhythmogenic right ventricular dysplasia; CABO
coronary bypass surgery; CAD = coronary artery disease; DCM = dilated cardiomyopathy; HTN
hypertension; MI = myocardial infarction; NYHA = New York Heart Association.
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was unclear, but may have reflected vasovagal response to
constipation. He recovered fully without sequelae.
Evaluation of Anticholinergic Effects (Table 3)
Maximal doses. The maximal administered dose of di-
sopyramide in patients receiving active pyridostigmine was
295 ± 75 mg orally every 6 hours. This dose was modestly
but significantly greater than that during placebo adminis-
tration (245 ± 100 mg every 6 hours) (p < 0.(5). The
maximal tolerable calculated dose for patients receiving
active pyridostigmine was 355 ± 90 mg every 6 hours,
compared with 260 ± 115 mg during placebo administration
(p < 0.001).
Side effects questionnaire. The maximal severity of
side effects reported by patients receiving any dose of di-
sopyramide, as reflected in the maximal questionnaire score,
was significantlyhigher for patients receiving disopyramide
alone than for patients receiving combination therapy with
pyridostigmine: 104.6 ± 2.8 versus 10\.9 ± 2.2, respec-
tively (p < 0.005). When questionnaire scores from both
treatment arms were paired at each of the comparable di-
sopyramide doses, patients receiving disopyramide alone
reported significantly more side effects (higher scores) than
did patients receiving disopyramide plus pyridostigmine:
1O\.2 ± 2.1 versus 100A ± \.0, respectively (p < 0.001).
Theoretically, trivial symptoms in each of the 20 categories
could produce an overall score suggesting severe effects.
or severe opposite effects could neutralize the score. How-
ever, this did not occur in any patient. As outlined, symp-
toms were confinedto only a few categories for each patient.
Overall, during therapy with disopyramide alone, I of
the 20 patients reported no anticholinergic symptoms; the
maximal severity of any side effect was reported to be "mild"
by 2 patients, "moderate" by I I, and "severe" by 6. In
contrast, during treatment with disopyramide plus pyrido-
stigrnine, six patients reported no anticholinergic symptoms
(p < 0.05 versus disopyramide alone); the maximal severity
of any symptom was reported to be "mild" by eight pa-
tients, "moderate" by f ve and" severe" by only one patient
(p < 0.005 versus disopyramide alone).
During treatment with disopyramide alone, 13 patients
reported urinary hesitation, with mild symptoms in 2 pa-
tients, moderate symptoms in 8 and severe symptoms in 2;
I patient reported urinary retention. During treatment with
disopyramide plus pyridostigmine, these symptoms were
significantly reduced: six patients reported urinary hesitation
(p < 0.03), with mild symptoms in five patients and mod-
erate symptoms in one patient (p < 0.02).
Dry mouth was reported in J7 patients receiving diso-
pyramide alone: it was reported to be mild in 9 patients,
moderate in 5 and severe in 3. This symptom was reported
in only six patients receiving disopyramide plus pyridostig-
mine (p < 0.006). and it was reported to be mild in four
patients and moderate in two (p < 0.04). Constipation or
abdominal cramps were reported in 10 patients receiving
disopyramidealone and in 2 patients receivingdisopyramide
plus pyridostigmine (p < 0.007). Other symptoms reported
in patients receiving disopyramide alone included dry eyes
or blurred vision in 12 patients, dizziness in 4 patients and
decreased appetite in 3 patients. Of patients receiving di-
sopyramide plus pyridostigmine, three reported dry eyes or
blurred vision (p < 0.004), five reported dizziness (p =
NS) and three reported decreased appetite (p = NS).
Only one patient reported any evidence of cholinergic
symptoms during the study. This patient developed muscle
fasciculations as evidence of a cholinergic response to pyr-
idostigmine during combination therapy. These fascicula-
tions disappeared as the disopyramide dose was increased.
Tear and saliva tests. The mean baseline tear produc-
tion of 13.8 ± 7.9 mm was significantly reduced to 8.1 ±
6.I mm during therapy with disopyramide alone (p < 0.001).
During disopyramide plus pyridostigmine treatment, tear
production was 11 .9 ± 6.2 mrn, a significant increase over
that during disopyramide monotherapy (p < O. 00 I) and
insignificantly different from baseline.
Baseline saliva production of 11.5 ± 3.7 cc was sig-
nificantly reduced to 8.6 ± 2.9 cc during disopyramide
monotherapy (p < 0.001). There was an increase toward
baseline during disopyramidecombination therapy with pyr-
idostigmine to 10.2 ± 4.2 cc, but this did not reach sta-
tistical significance (p = NS compared with disopyramide
alone; p < 0.025 compared with baseline).
Table 3. Evaluation of Maximal Doses of Disopyramide and Anticholinergic Effects
No. of Disopyramide + Disopyramide
Patients Pyridostigmine p Value Alone
Maximal administered 20 295 ± 75 <0.05 245 ± 100
dose (mg every 6 hours)
Maximal tolerable 20 355 ± 190 <0.005 260 ± 115
dose (mg every 6 hours)
Maximal side effects: 20 101.9 ± 2.2 <0.005 104.6 ± 2.S
questionnaire score
All side effects: (135 paired 100.4 ± 1.0 < o.oo I 101.1 ± 2.1
questionnaire scores (paired) scores
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Figure2. Results of Holter ambulatoryelectrocardiographic mon-
itoring, showingthe frequency of premature ventricular complexes
(PVes) in 17 patients. B = baseline; 0 = disopyramide; P =
pyridostigmine.
1 I
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Figure3. Results of Holter ambulatoryelectrocardiographic mon-
itoring, showing maximal grade of ventricular ectopic arrhythmias
in 17 patients. Histograms show the number of patients with each
degree of severity of ventricular arrhythmia. VT = ventricular
tachycardia; other abbreviations as in Figure 2.
B
during their baseline study; all but I of these 16 patients
had ventricular tachycardia that remained inducible during
treatment with disopyramide alone and in combination with
pyridostigmine. There was no substantial change in the
methods required to induce ventricular tachycardia during
treatment as compared with baseline. In all 16patients whose
ventricular tachycardia remained inducible throughout the
study. there was a significant reduction in tachycardia rate
during treatment with disopyramide that persisted during
therapy with disopyramide plus pyridostigmine. The mean
induced tachycardia cycle length at baseline was 250 ± 40
compared with 340 ± 60 ms during disopyramide therapy
(p < 0 .001) and 360 ± 60 ms during disopyramide plus
pyridostigmine therapy (p < 0.001 compared with baseline;
p = NScompared with disopyramide alone). Of six patients
who required cardioversion to terminate ventricular tachy-
cardia induced during the baseline study, only one patient
required cardioversion during treatment with disopyramide
and again during combined therapy.
The mean baseline ventricular effective refractory period
during pacing at standardized cycle lengths was 250 ± 40
ms. The refractory period with disopyramide treatment dur-
ing pacing at comparable cycle lengths was prolonged to
300 :t 20 ms (p < O.00 I). This prolongation was unchanged
(300 ± 30 ms) during pacing at similar cycle lengths with
disopyramide plus pyridostigmine therapy.
The mean QTc interval (Bazell's correction [f8]) was
prolonged from 0.44 ± 0.03 second at baseline to 0.47 ±
0 .03 second during disopyramide treatment (p < 0 .005 ).
During treatment with disopyramide plus pyridostigmine ,
the QTc interval remained prolonged at 0.48 ± 0.04 second
(p < 0.001 compared with baseline; p = NS compared
with disopyramide alone).
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Evaluation of Antiarrhythmic Effects
Holter monitoring (Fig. 2). Ambulatory electrocardio-
graphic monitoring from each of the three study periods
(baseline, disopyramide alone and disopyramide plus pyr-
idostigmine) was available in 19 patients. Two of these
patients are not included because baseline recordings showed
< 10 ventricular premature complexes/h (2.6 and O.O/h) and,
therefore, changes in frequency could not be attributed to
pharmacologic manipulation (16,17). Of the remaining 17
patients, 15 had at least a 50% reduction in hourly frequency
of ventricular premature complexes during treatment with
disopyramide alone. These decreases persisted during com-
bination therapy with pyridostigmine.
The maximal complexity of arrhythmia documented in
these / 7 patients is shown in Figure 3 . Sixteen patients had
a reduction in maximal Lown classification grade (I I) dur-
ing treatment with disopyrarnide , and II of the 16 had a
reduction of at least two Lown grades. This reduction per-
sisted during disopyramide plus pyridostigmine therapy in
12 of the 16 patients. In the remaining four patients, ven-
tricular couplets and tachycardia remained suppressed dur-
ing combination therapy despite an increase in maximal
grade of arrhythmia from grade I or 2 during disopyramide
treatment to grade 3 during combined therapy with pyri-
dostigmine.
Electrophysiology and electrocardiography. Pro-
grammed electrical stimulation of the ventricles was carried
out during all three testing periods in 17 patients. Sixteen
of these 17 patients had ventricular tachycardia induced
lACC Vol. 10, No.3
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Condition
Exercise variables
Maximal heart rate (beats/min)
Maximal blood pressure (systolic) (rnm Hg:
Total exercise duration (min)
Maximal work load achieved (kp-m/min)
Baseline
139 ± 17
173 ± 18
5.1 ± 2.1
441 ± 140
Disopyramide
Alone
136 ± 21
165 ± 16
4.4 ± 2.0
450 ± 137
Disopyramide +
Pyridostigmine
134 ± 19
162 ± 16
4.7 ± 2.1
433 ± 127
All differences, p = NS: 450 kp-rn/rnin = 75 W.
Exercise stress testing. Exercise stress testing was car-
ried out during all three study conditions in 14 patients. Ten
of the 14 patients had exercise-induced ventricular couplets
or ventricular tachycardia during baseline recording. In 8
of these 10 patients, disopyramide alone eliminated these
higher forms of ventricular ectopic rhythm. This improve-
ment persisted during therapy with disopyramide plus pyr-
idostigmine. The remaining two patients with persistent ex-
ercise-induced ventricular tachycardia during disopyramide
plus placebo therapy tolerated higher doses of disopyramide
during combination therapy with pyridostigmine and this
tachycardia was eliminated.
There were no significant differences among values at
baseline and during treatment with disopyramide alone and
disopyramide plus pyridostigmine in the following clinical
variables during exercise (Table 4): maximal heart rate
achieved, maximal blood pressure achieved, maximal work-
load achieved and number of minutes exercised.
Evaluation of Other Effects
During treatment with disopyramide, no patient in this
study had precipitation or exacerbation of congestive heart
failure. No patient demonstrated aggravation of baseline
arrhythmias.
Blood level determinations. Disopyramide blood levels
were compared using paired samples from each arm of the
study, drawn after comparable dosages. The mean peak and
trough blood levels during disopyramide with placebo ther-
apy were 4.25 ± 1.93 and 3.50 ± 1.86 jlg/ml, respec-
tively. These levels did not differ significantly from mean
peak and trough levels during disopyramide plus pyrido-
stigrnine therapy (4.30 ± 1.35 and 3.53 ± 1.49 jLglmL
respectively).
Discussion
The use of a second therapeutic modality to counteract
undesirable adverse effects of a primary therapy is not un-
usual in cardiovascular medicine. Common clinical situa-
tions include potassium supplementation for the hypokale-
mia induced by furosemide and thiazide diuretic drugs, the
use of digoxin to prevent' 'paradoxic" increases in the ven-
tricular response to atrial flutter during treatment with type
I antiarrhythmic agents, anticoagulant therapy to prevent
the thrombotic and embolic complications of certain pros-
thetic heart valves and the use of pacemakers to prevent
excessive bradycardia during treatment with potent negative
chronotropic agents.
The results of this study indicate that in patients who are
suitable for a clinical trial of disopyramide, sustained release
pyridostigmine can be safely used to reduce substantially
the incidence and severity of anticholinergic side effects
attributable to disopyramide. Pyridostigmine caused no
measurable alterations in the electrophysiologic or antiar-
rhythmic effects of disopyramide.
Disopyramide-pyridostigmine interaction. Disopyr-
amide is a first line antiarrhythmic agent with documented
(1,3,5) efficacy in the treatment of ventricular and supra-
ventricular tachyarrhythmias. Disopyramide has been shown
to have a dual effect (19,20) on the heart: I) direct effects
similar to those of other type I antiarrhythmic agents, with
depression of conduction and automaticity (19-21), and 2)
potent anticholinergic properties that produce indirect ef-
fects by means of the parasympathetic nervous system and
can mask the drug's direct effects (19,20.22). The anticho-
linergic properties of disopyramide are mediated by a com-
petitive inhibition of muscarinic receptors (23).
Pyridostigmine , an analog of neostigmine. competitively
inhibits acetylcholinesterase, the enzyme that degrades the
parasympathetic neurotransmitter acetylcholine. Pyridostig-
mine is used clinically to treat myasthenia gravis by in-
creasing synaptic acetylcholine, thereby overcoming the in-
hibition of postsynaptic acetylcholine receptors by the
autoantibodies responsible for the disease (24). As a cho-
linergic agent. pyridostigmine has been used occasionally
as an oral edrophonium equivalent for the treatment of cer-
tain supraventricular arrhythmias (9). Rarely, it has been
used in the treatment of sustained ventricular tachycardia
unresponsive to other means of therapy (25). The electro-
physiologic and antiarrhythmic properties of pyridostigmine
have not been studied in detail.
Both the antiarrhythmic efficacy and anticholinergic side
effects of disopyramide are directly related to blood con-
centrations (4.12,26,27). It has been suggested (2,28) that
the anticholinergic properties of disopyramide may actually
contribute to antiarrhythmic efficacy. Two lines of evidence
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indicate that this is not the case: I) in the denervated trans-
planted human heart, the antiarrhythmic properties are due
to the direct electrophysiologic effects (29), and 2) the abil-
ity of pyridostigmine to reverse selectively the anticholin-
ergic effects of disopyramide while preserving the electro-
physiologic and antiarrhythmic properties was demonstrated
in the present study. The reversal of anticholinergic prop-
erties is presumably due to the increased acetylcholine in
the synapses overcoming the competitive inhibition of di-
sopyramide for postsynaptic receptor sites. Such an expla-
nation would be consistent with the experience of the one
patient in this study who developed evidence of cholinergic
overactivity (muscle fasciculations) that disappeared with
an increased dose of disopyramide. The effects of pyrido-
stigmine cannot be easily explained by an alteration in di-
sopyramide pharmacokinetics or metabolism in view of the
absence of an effect of pyridostigmine on disopyramide
blood levels.
Anticholinergic effects. As determined by the side ef-
fects questionnaire, pyridostigmine reduced the incidence
and severity of the anticholinergic symptoms caused by
disopyramide at all dose levels. The maximal dose of di-
sopyramide tolerated by patients was significantly increased
during combination therapy with pyridostigmine. This latter
point may have important clinical implications because the
antiarrhythmic efficacy of disopyramide directly correlates
with blood levels (26,27). The results of objective mea-
surements of anticholinergic activity, the Schirmer tear pro-
duction test and the saliva production test indicate that sub-
jectively reported improvements in anticholinergic symptoms
were caused by a true reversal toward normal of the diso-
pyramide-induced decreases in tear and saliva production.
The one patient with symptomatic prostatic hypertrophy
illustrates the potency of pyridostigmine in reversing anti-
cholinergic side effects. This patient developed transient
urinary retention that required bladder catheterization while
receiving 200 mg of disopyramide alone every 6 hours dur-
ing the crossover arm of the study. He had experienced no
change in his baseline urinary ability during the initial arm
of the study while receiving as much as 300 mg of diso-
pyramide every 6 hours in combination with pyridostigmine.
The number of patients reporting anticholinergic symp-
toms during this study was considerably higher than the 20
to 40% incidence rate reported elsewhere (2-4). This was
directly related to our study design, which called for higher
doses of disopyramide than those usually used clinically.
Antiarrhythmic effects. The purpose of this part of our
study was to document, if present, a pyridostigmine-induced
reversal of the antiarrhythmic effects of disopyramide. The
methods chosen have been shown to be able to document
noninvasively (Holter ambulatory ECG monitoring and ex-
ercise stress testing) (30,31) and invasively (programmed
electrical stimulation of the ventricles) (9,10,32-34) the
antiarrhythmic efficacy of a therapeutic agent. Furthermore,
the use of a catheter electrode in the ventricle allowed the
measurement of refractory periods taken as an electrophys-
iologic effect of disopyramide (2,35). All electrophysiologic
and antiarrhythmic effects documented during monotherapy
persisted during combination therapy with pyridostigmine.
Limitations. A potential shortcoming of this study was
that measurements of the effects of disopyramide on atrial
electrophysiologic variables and those of the specialized
conduction system were not made. The parasympathetic
nervous system has been shown (36,37) to exert a more
significant influence on the sinus node and atrioventricular
node than on the ventricles. The effectiveness of disopyr-
amide plus pyridostigmine against arrhythmias involving
these structures cannot be evaluated on the basis of the
results of this study. These patients did not undergo hemo-
dynamic assessment during therapy with disopyramide alone
or in combination with pyridostigmine. However, no dif-
ferences were observed in measured variables clinically or
during exercise testing.
Conclusions. The definition of "antidote" (from the
Greek, anti-against, dotos-given) is " ... a remedy to
counteract the effects of .... anything noxious taken into
the system." The results of this study indicate that sustained-
release pyridostigmine can be safely used as an antidote for
the undesirable anticholinergic properties of disopyramide.
Pyridostigmine selectively reverses the anticholinergic side
effects of disopyramide while leaving the electrophysiologic
and antiarrhythmic properties intact. This should allow for
more widespread clinical use of disopyramide in patients
who are suitable candidates, but who otherwise could not
tolerate disopyramide. It remains to be determined whether
the higher doses and blood levels of disopyramide attainable
through combination therapy with pyridostigmine will result
in greater antiarrhythmic efficacy.
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